Evidence map›Paper›PMID 39719161›Full record

ReviewPharmacology, biochemistry, and behavior2025

Emerging medications and pharmacological treatment approaches for substance use disorders.

Joel S Raymond, Alexander G Athanasopoulos, Connie J Badolato, Tylah J Doolan, Rhianne L Scicluna, Nicholas A Everett, Michael T Bowen, Morgan H James

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology, biochemistry, and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Drug Therapy.Advances in experimental medicine and biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joel S RaymondDepartment of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, NJ, USA.
Alexander G AthanasopoulosSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Connie J BadolatoSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Tylah J DoolanSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Rhianne L SciclunaSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Nicholas A EverettSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Michael T BowenSchool of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Morgan H JamesDepartment of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA; Rutgers Addiction Research Center, Brain Health Institute, Rutgers Health, Piscataway, NJ, USA; School of Psychology, Faculty of Science, University of Sydney, Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. Electronic address: morgan.james@rutgers.edu.

Funding

ROLE OF OREXIN IN COCAINE DEMAND AND ADDICTIONR01DA006214 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Gary S. Aston-Jones · 1989 to 2024
$2.5M
Orexin (hypocretin) signaling in ventral tegmental area as a common mediator of sleep disturbances and drug demand in cocaine abstinenceR01DA061303 · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2025 to 2025
$373k
The orexin system as a novel mediator of depression-like outcomes in female rats exposed to an endocrine disrupting compound during the peripubertal periodR21ES035848 · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2025 to 2025
$196k
NHLBI NIH HHS U01 HL150852NIDA NIH HHS R00 DA045765NIDA NIH HHS R00 DA04765NIDA NIH HHS R01 DA006214NIDA NIH HHS R01 DA061303NIDA NIH HHS R37 DA061303NIEHS NIH HHS R21 ES035848
6 · The paper itself

Abstract

Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have contributed to this paucity, including the biological complexity of addiction, regulatory challenges, and a historical lack of enthusiasm among pharmaceutical companies to commit resources to this disease space. Despite these headwinds, the recent opioid crisis has highlighted the devastating consequences of SUDs for both individuals and society, stimulating urgent efforts to identify novel treatment approaches. In addition, several neurobiological systems have been recently implicated in unique aspects of drug reward, opening the door to candidate medications with novel mechanisms of action. Here, we provide an overview of efforts to target several of these new systems, with a focus on those that are the subject of ongoing clinical trials as well as being areas of interest among the authors' research groups (MHJ, MTB, NAE). Specifically, we discuss new classes of medications targeting the serotonin 2A receptor (i.e., psychedelics), glucagon-like peptide 1 receptor, cannabidiol, dynorphin/kappa opioid receptor, orexin/hypocretin, and oxytocin receptor systems, as well as emergent approaches for modulating the more canonical dopaminergic system via agonist therapies for stimulant use disorders. Collectively, innovations in this space give reason for optimism for an improved therapeutic landscape for substance use disorders in the near future.

Indexed as

Substance-Related DisordersAnimalsHallucinogensHumansHallucinogens

Identifiers

PMID39719161
PMCPMC12078786

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.